Literature DB >> 25196832

Bayesian designs and the control of frequentist characteristics: a practical solution.

Steffen Ventz1, Lorenzo Trippa1.   

Abstract

Frequentist concepts, such as the control of the type I error or the false discovery rate, are well established in the medical literature and often required by regulators. Most Bayesian designs are defined without explicit considerations of frequentist characteristics. Once the Bayesian design is structured, statisticians use simulations and adjust tuning parameters to comply with a set of targeted operating characteristics. These adjustments affect the use of prior information and utility functions. Here we consider a Bayesian decision theoretic approach for experimental designs with explicit frequentist requisites. We define optimal designs under a set of constraints required by a regulator. Our approach combines the use of interpretable utility functions with frequentist criteria, and selects an optimal design that satisfies a set of required operating characteristics. We illustrate the approach using a group-sequential multi-arm Phase II trial and a bridging trial.
© 2014, The International Biometric Society.

Keywords:  Bayesian design; Clinical trials; Decision theory; Frequentist constraints

Mesh:

Year:  2014        PMID: 25196832     DOI: 10.1111/biom.12226

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  3 in total

1.  Adaptive designs in clinical trials: why use them, and how to run and report them.

Authors:  Philip Pallmann; Alun W Bedding; Babak Choodari-Oskooei; Munyaradzi Dimairo; Laura Flight; Lisa V Hampson; Jane Holmes; Adrian P Mander; Lang'o Odondi; Matthew R Sydes; Sofía S Villar; James M S Wason; Christopher J Weir; Graham M Wheeler; Christina Yap; Thomas Jaki
Journal:  BMC Med       Date:  2018-02-28       Impact factor: 8.775

2.  A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP).

Authors:  Patrick P J Phillips; Kelly E Dooley; Stephen H Gillespie; Norbert Heinrich; Jason E Stout; Payam Nahid; Andreas H Diacon; Rob E Aarnoutse; Gibson S Kibiki; Martin J Boeree; Michael Hoelscher
Journal:  BMC Med       Date:  2016-03-23       Impact factor: 8.775

3.  Unbiased estimation for response adaptive clinical trials.

Authors:  Jack Bowden; Lorenzo Trippa
Journal:  Stat Methods Med Res       Date:  2015-08-11       Impact factor: 3.021

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.